PDCD1 and urinary bladder cancer: Furthermore, HC-5404 and anti-PD-1 combination therapy significantly enhanced antitumor efficacy in a syngeneic mouse bladder cancer model, correlated with increased immune activation markers on tumor cells and TAMs, including IFNAR1 and calreticulin, and reduced immunosuppressive activity of MDSCs [243].